Bausch Health Companies Inc (NYSE:BHC) – Investment analysts at Jefferies Financial Group cut their Q4 2018 earnings per share estimates for shares of Bausch Health Companies in a research note issued on Tuesday, November 6th. Jefferies Financial Group analyst D. Steinberg now expects that the company will earn $0.66 per share for the quarter, down from their prior estimate of $0.67.

A number of other brokerages have also recently issued reports on BHC. Zacks Investment Research raised Bausch Health Companies from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a report on Wednesday, October 3rd. ValuEngine cut Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Tuesday, October 2nd. TD Securities upped their target price on Bausch Health Companies from $24.00 to $28.00 and gave the stock a “hold” rating in a report on Wednesday. Royal Bank of Canada upped their target price on Bausch Health Companies from $30.00 to $31.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, Mizuho reaffirmed a “buy” rating and issued a $35.00 target price on shares of Bausch Health Companies in a report on Monday, October 8th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Bausch Health Companies currently has a consensus rating of “Hold” and an average target price of $27.55.

Shares of BHC opened at $27.20 on Thursday. Bausch Health Companies has a 12-month low of $13.86 and a 12-month high of $28.45. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 7.55. The stock has a market capitalization of $9.48 billion, a price-to-earnings ratio of 6.87, a PEG ratio of 0.37 and a beta of -0.28.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.31. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The business had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.09 billion. The business’s revenue was down 3.7% on a year-over-year basis.

Several hedge funds have recently modified their holdings of the company. Canada Pension Plan Investment Board acquired a new stake in shares of Bausch Health Companies in the third quarter valued at about $38,497,000. Trexquant Investment LP bought a new stake in shares of Bausch Health Companies during the 3rd quarter valued at about $1,904,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Bausch Health Companies during the 3rd quarter valued at about $703,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Bausch Health Companies during the 3rd quarter valued at about $3,395,000. Finally, Ontario Teachers Pension Plan Board bought a new stake in shares of Bausch Health Companies during the 3rd quarter valued at about $855,000. 42.90% of the stock is owned by institutional investors.

In other news, EVP Christina Ackermann sold 19,946 shares of the stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total value of $498,251.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Paul Herendeen purchased 10,000 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was bought at an average cost of $22.61 per share, with a total value of $226,100.00. The disclosure for this purchase can be found here. In the last three months, insiders bought 165,000 shares of company stock valued at $3,890,700. Insiders own 11.54% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Article: Why do companies issue stock splits?

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.